CRISPR screening identifies T cell-intrinsic regulators of CD3-bispecific antibody responses.
Bispecific antibodies
CRISPR screening
EP300
T cells
immunotherapy
mTOR
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
31
03
2022
accepted:
11
07
2022
entrez:
22
8
2022
pubmed:
23
8
2022
medline:
24
8
2022
Statut:
epublish
Résumé
CD3-engaging bispecific antibodies (BsAbs) enable the formation of an immune synapse between T cells and tumor cells, resulting in robust target cell killing not dependent on a preexisting tumor specific T cell receptor. While recent studies have shed light on tumor cell-specific factors that modulate BsAb sensitivity, the T cell-intrinsic determinants of BsAb efficacy and response durability are poorly understood. To better clarify the genes that shape BsAb-induced T cell responses, we conducted targeted analyses and a large-scale unbiased
Identifiants
pubmed: 35990699
doi: 10.3389/fimmu.2022.909979
pmc: PMC9388929
doi:
Substances chimiques
Antibodies, Bispecific
0
Receptors, Antigen, T-Cell
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
909979Informations de copyright
Copyright © 2022 Molony, Funk, Trabucco, Corcoran, Ruddy, Varadarajan, Elliot, Piquet, Lam, Meyer, Wang, Kurtulus and Lu.
Déclaration de conflit d'intérêts
Authors RM, TF, GT, EC, DR, MP, JL, HW, and HL are currently employed by the Novartis Institutes for Biomedical Research (NIBR). The following authors were previously employed by NIBR when they were involved with the work described herein: MV (currently employed by Arbor Biotechnologies), GE (currently employed by Foghorn Therapeutics), MM (currently employed by Bristol Myers Squibb), and SK (currently employed by 2seventy Bio).
Références
Exp Hematol Oncol. 2017 May 18;6:14
pubmed: 28533941
Annu Rev Pathol. 2009;4:127-50
pubmed: 18767981
EMBO J. 1985 Feb;4(2):337-44
pubmed: 2410254
Cell. 2018 Dec 13;175(7):1958-1971.e15
pubmed: 30449619
J Clin Oncol. 2014 Dec 20;32(36):4134-40
pubmed: 25385737
J Immunol. 2017 Mar 1;198(5):1910-1920
pubmed: 28115529
Science. 2017 May 5;356(6337):513-519
pubmed: 28473584
Curr Opin Immunol. 2017 Jun;46:103-111
pubmed: 28535458
Nat Commun. 2018 Apr 19;9(1):1558
pubmed: 29674694
Int J Cancer. 2010 Nov 1;127(9):2209-21
pubmed: 20473913
Blood. 2017 Jan 5;129(1):100-104
pubmed: 27784674
Growth Factors. 2007 Aug;25(4):209-26
pubmed: 18092230
Cancer Immunol Res. 2021 Jan;9(1):34-49
pubmed: 33177106
Cell Metab. 2018 Dec 4;28(6):922-934.e4
pubmed: 30174303
Oncotarget. 2016 May 10;7(19):28059-74
pubmed: 27058902
Sci Adv. 2021 Feb 26;7(9):
pubmed: 33637530
Proc Natl Acad Sci U S A. 1990 Sep;87(18):7220-4
pubmed: 2144901
Nat Immunol. 2015 Aug;16(8):871-9
pubmed: 26147684
Nature. 1985 Apr 18-24;314(6012):628-31
pubmed: 2859527
Am J Hematol. 2017 Sep;92(9):858-865
pubmed: 28494518
Immunity. 2011 Nov 23;35(5):792-805
pubmed: 22118527
J Control Release. 2017 Oct 10;263:151-161
pubmed: 28257991
Pharmacol Ther. 2018 May;185:122-134
pubmed: 29269044
Immunity. 2010 Jan 29;32(1):67-78
pubmed: 20060330
Front Immunol. 2018 Dec 07;9:2900
pubmed: 30581443
Mol Cancer Ther. 2019 Feb;18(2):312-322
pubmed: 30381448
Sci Transl Med. 2019 Sep 4;11(508):
pubmed: 31484792
Mol Cell. 2013 Nov 21;52(4):495-505
pubmed: 24095279
Nat Med. 2013 Sep;19(9):1173-7
pubmed: 23955711
Int J Mol Sci. 2022 Mar 15;23(6):
pubmed: 35328563
J Allergy Clin Immunol. 2009 Apr;123(4):758-62
pubmed: 19348914
Cancer Cell. 2018 Nov 12;34(5):775-791.e3
pubmed: 30423297
Sci Transl Med. 2018 Jul 11;10(449):
pubmed: 29997249
Mol Immunol. 2006 Feb;43(6):763-71
pubmed: 16360021
Drugs Context. 2021 Sep 21;10:
pubmed: 34603459
Cell Immunol. 2010;262(2):89-95
pubmed: 20236628
Nat Med. 2019 Jan;25(1):95-102
pubmed: 30559422
Nat Methods. 2018 Nov;15(11):941-946
pubmed: 30297964
Semin Immunol. 2019 Aug;44:101344
pubmed: 31727465
Nutrients. 2017 Oct 27;9(11):
pubmed: 29077002
J Biol Chem. 2016 Jun 17;291(25):13014-27
pubmed: 27056325
Nat Rev Drug Discov. 2019 Aug;18(8):585-608
pubmed: 31175342
J Immunol. 1994 Mar 1;152(5):2385-92
pubmed: 8133049